I keep bouncing between the Phase 2 obesity result and the company Phase 3 slides. Phase 2 showed mean body-weight reduction of 24.2% at 48 weeks under the efficacy estimand.
Company-reported Phase 3, not peer-reviewed, says up to 28.7% across four trials. That's a ~4.5 point gap. Is it estimand, duration, population, or selected dose arms? Also the completed CTgov trials are small: 32 Chinese participants, 445 with knee OA, 46 postmenopausal women.
Do those add anything to the efficacy picture, or are they mostly safety/regional slices?